RNXT
RenovoRx Inc
NASDAQ: RNXT · HEALTHCARE · BIOTECHNOLOGY
$0.85
+2.27% today
Updated 2026-04-30
Market cap
$37.84M
P/E ratio
—
P/S ratio
33.70x
EPS (TTM)
$-0.32
Dividend yield
—
52W range
$1 – $1
Volume
0.4M
RenovoRx Inc (RNXT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $43000.00 | $1.12M |
| Revenue growth (YoY) | — | — | — | — | — | — | +2511.6% |
| Cost of revenue | — | — | $9000.00 | $6000.00 | $0.00 | $0.00 | $327000.00 |
| Gross profit | — | — | $-9000.00 | $-6000.00 | $0.00 | $43000.00 | $796000.00 |
| Gross margin | — | — | — | — | — | 100.0% | 70.9% |
| R&D | $3.00M | $2.39M | $3.04M | $4.30M | $5.67M | $6.03M | $6.27M |
| SG&A | $899000.00 | $818000.00 | $2.63M | $5.65M | $5.73M | $4.99M | $7.04M |
| Operating income | $-3.90M | $-3.20M | $-5.67M | $-9.95M | $-11.40M | $-10.97M | $-12.51M |
| Operating margin | — | — | — | — | — | -25511.6% | -1114.0% |
| EBITDA | $-3.84M | $-3.21M | $-5.48M | $-9.94M | $-11.39M | $-10.97M | $-12.51M |
| EBITDA margin | — | — | — | — | — | -25511.6% | -1114.0% |
| EBIT | $-3.90M | $-6.41M | $-5.49M | $-9.95M | $-11.40M | $-10.97M | — |
| Interest expense | $0.00 | $590000.00 | $834000.00 | $57000.00 | $108000.00 | $384000.00 | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-3.84M | $-3.80M | $-6.32M | $-9.77M | $-10.23M | $-8.81M | $-11.17M |
| Net income growth (YoY) | — | +1.1% | -66.5% | -54.5% | -4.7% | +13.9% | -26.7% |
| Profit margin | — | — | — | — | — | -20497.7% | -994.5% |